Global Chemotherapy Drugs for Neuroblastoma Supply, Demand and Key Producers, 2023-2029
The global Chemotherapy Drugs for Neuroblastoma market size is expected to reach $ 171.1 million by 2029, rising at a market growth of 4.4% CAGR during the forecast period (2023-2029).
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
This report studies the global Chemotherapy Drugs for Neuroblastoma production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Chemotherapy Drugs for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chemotherapy Drugs for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Chemotherapy Drugs for Neuroblastoma total production and demand, 2018-2029, (K Units)
Global Chemotherapy Drugs for Neuroblastoma total production value, 2018-2029, (USD Million)
Global Chemotherapy Drugs for Neuroblastoma production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Chemotherapy Drugs for Neuroblastoma domestic production, consumption, key domestic manufacturers and share
Global Chemotherapy Drugs for Neuroblastoma production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Chemotherapy Drugs for Neuroblastoma market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chemotherapy Drugs for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Chemotherapy Drugs for Neuroblastoma Market, By Region:
1. How big is the global Chemotherapy Drugs for Neuroblastoma market?
2. What is the demand of the global Chemotherapy Drugs for Neuroblastoma market?
3. What is the year over year growth of the global Chemotherapy Drugs for Neuroblastoma market?
4. What is the production and production value of the global Chemotherapy Drugs for Neuroblastoma market?
5. Who are the key producers in the global Chemotherapy Drugs for Neuroblastoma market?
6. What are the growth factors driving the market demand?
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
This report studies the global Chemotherapy Drugs for Neuroblastoma production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Chemotherapy Drugs for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chemotherapy Drugs for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Chemotherapy Drugs for Neuroblastoma total production and demand, 2018-2029, (K Units)
Global Chemotherapy Drugs for Neuroblastoma total production value, 2018-2029, (USD Million)
Global Chemotherapy Drugs for Neuroblastoma production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Chemotherapy Drugs for Neuroblastoma domestic production, consumption, key domestic manufacturers and share
Global Chemotherapy Drugs for Neuroblastoma production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Chemotherapy Drugs for Neuroblastoma production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Chemotherapy Drugs for Neuroblastoma market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chemotherapy Drugs for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Chemotherapy Drugs for Neuroblastoma Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Cyclophosphamide
- Cisplatin or Carboplatin
- Vincristine
- Doxorubicin (Adriamycin)
- Etoposide
- Other
- Hospital
- Clinic
- Other
- Baxter Healthcare
- Ingenus Pharmaceuticals
- ANI Pharmaceuticals
- Teva Pharmaceuticals
- Qilu Pharmaceutical
- Pfizer
- Hikma Pharmaceuticals
- Fresenius Kabi
- Accord Healthcare
- Viatris
1. How big is the global Chemotherapy Drugs for Neuroblastoma market?
2. What is the demand of the global Chemotherapy Drugs for Neuroblastoma market?
3. What is the year over year growth of the global Chemotherapy Drugs for Neuroblastoma market?
4. What is the production and production value of the global Chemotherapy Drugs for Neuroblastoma market?
5. Who are the key producers in the global Chemotherapy Drugs for Neuroblastoma market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Chemotherapy Drugs for Neuroblastoma Introduction
1.2 World Chemotherapy Drugs for Neuroblastoma Supply & Forecast
1.2.1 World Chemotherapy Drugs for Neuroblastoma Production Value (2018 & 2022 & 2029)
1.2.2 World Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.2.3 World Chemotherapy Drugs for Neuroblastoma Pricing Trends (2018-2029)
1.3 World Chemotherapy Drugs for Neuroblastoma Production by Region (Based on Production Site)
1.3.1 World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018-2029)
1.3.2 World Chemotherapy Drugs for Neuroblastoma Production by Region (2018-2029)
1.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
1.3.4 North America Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.5 Europe Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.6 China Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.7 Japan Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Chemotherapy Drugs for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Chemotherapy Drugs for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Chemotherapy Drugs for Neuroblastoma Demand (2018-2029)
2.2 World Chemotherapy Drugs for Neuroblastoma Consumption by Region
2.2.1 World Chemotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023)
2.2.2 World Chemotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029)
2.3 United States Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.4 China Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.5 Europe Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.6 Japan Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.7 South Korea Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.8 ASEAN Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.9 India Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
3 WORLD CHEMOTHERAPY DRUGS FOR NEUROBLASTOMA MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Chemotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023)
3.2 World Chemotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023)
3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Chemotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Chemotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Chemotherapy Drugs for Neuroblastoma in 2022
3.5.3 Global Concentration Ratios (CR8) for Chemotherapy Drugs for Neuroblastoma in 2022
3.6 Chemotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.6.1 Chemotherapy Drugs for Neuroblastoma Market: Region Footprint
3.6.2 Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.6.3 Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Comparison
4.1.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Comparison
4.2.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Comparison
4.3.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.4.3 United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
4.5 China Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share
4.5.1 China Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.5.3 China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
4.6 Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Chemotherapy Drugs for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Cyclophosphamide
5.2.2 Cisplatin or Carboplatin
5.2.3 Vincristine
5.2.4 Doxorubicin (Adriamycin)
5.2.5 Etoposide
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Chemotherapy Drugs for Neuroblastoma Production by Type (2018-2029)
5.3.2 World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2018-2029)
5.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Chemotherapy Drugs for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Chemotherapy Drugs for Neuroblastoma Production by Application (2018-2029)
6.3.2 World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2018-2029)
6.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Baxter Healthcare
7.1.1 Baxter Healthcare Details
7.1.2 Baxter Healthcare Major Business
7.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
7.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Baxter Healthcare Recent Developments/Updates
7.1.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.2 Ingenus Pharmaceuticals
7.2.1 Ingenus Pharmaceuticals Details
7.2.2 Ingenus Pharmaceuticals Major Business
7.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.2.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.3 ANI Pharmaceuticals
7.3.1 ANI Pharmaceuticals Details
7.3.2 ANI Pharmaceuticals Major Business
7.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 ANI Pharmaceuticals Recent Developments/Updates
7.3.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Details
7.4.2 Teva Pharmaceuticals Major Business
7.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Teva Pharmaceuticals Recent Developments/Updates
7.4.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Qilu Pharmaceutical
7.5.1 Qilu Pharmaceutical Details
7.5.2 Qilu Pharmaceutical Major Business
7.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
7.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Qilu Pharmaceutical Recent Developments/Updates
7.5.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
7.6 Pfizer
7.6.1 Pfizer Details
7.6.2 Pfizer Major Business
7.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
7.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Pfizer Recent Developments/Updates
7.6.6 Pfizer Competitive Strengths & Weaknesses
7.7 Hikma Pharmaceuticals
7.7.1 Hikma Pharmaceuticals Details
7.7.2 Hikma Pharmaceuticals Major Business
7.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Hikma Pharmaceuticals Recent Developments/Updates
7.7.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Fresenius Kabi
7.8.1 Fresenius Kabi Details
7.8.2 Fresenius Kabi Major Business
7.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
7.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Fresenius Kabi Recent Developments/Updates
7.8.6 Fresenius Kabi Competitive Strengths & Weaknesses
7.9 Accord Healthcare
7.9.1 Accord Healthcare Details
7.9.2 Accord Healthcare Major Business
7.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
7.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Accord Healthcare Recent Developments/Updates
7.9.6 Accord Healthcare Competitive Strengths & Weaknesses
7.10 Viatris
7.10.1 Viatris Details
7.10.2 Viatris Major Business
7.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
7.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Viatris Recent Developments/Updates
7.10.6 Viatris Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Chemotherapy Drugs for Neuroblastoma Industry Chain
8.2 Chemotherapy Drugs for Neuroblastoma Upstream Analysis
8.2.1 Chemotherapy Drugs for Neuroblastoma Core Raw Materials
8.2.2 Main Manufacturers of Chemotherapy Drugs for Neuroblastoma Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Chemotherapy Drugs for Neuroblastoma Production Mode
8.6 Chemotherapy Drugs for Neuroblastoma Procurement Model
8.7 Chemotherapy Drugs for Neuroblastoma Industry Sales Model and Sales Channels
8.7.1 Chemotherapy Drugs for Neuroblastoma Sales Model
8.7.2 Chemotherapy Drugs for Neuroblastoma Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Chemotherapy Drugs for Neuroblastoma Introduction
1.2 World Chemotherapy Drugs for Neuroblastoma Supply & Forecast
1.2.1 World Chemotherapy Drugs for Neuroblastoma Production Value (2018 & 2022 & 2029)
1.2.2 World Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.2.3 World Chemotherapy Drugs for Neuroblastoma Pricing Trends (2018-2029)
1.3 World Chemotherapy Drugs for Neuroblastoma Production by Region (Based on Production Site)
1.3.1 World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018-2029)
1.3.2 World Chemotherapy Drugs for Neuroblastoma Production by Region (2018-2029)
1.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
1.3.4 North America Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.5 Europe Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.6 China Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.3.7 Japan Chemotherapy Drugs for Neuroblastoma Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Chemotherapy Drugs for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Chemotherapy Drugs for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Chemotherapy Drugs for Neuroblastoma Demand (2018-2029)
2.2 World Chemotherapy Drugs for Neuroblastoma Consumption by Region
2.2.1 World Chemotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023)
2.2.2 World Chemotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029)
2.3 United States Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.4 China Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.5 Europe Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.6 Japan Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.7 South Korea Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.8 ASEAN Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
2.9 India Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029)
3 WORLD CHEMOTHERAPY DRUGS FOR NEUROBLASTOMA MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Chemotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023)
3.2 World Chemotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023)
3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Chemotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Chemotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Chemotherapy Drugs for Neuroblastoma in 2022
3.5.3 Global Concentration Ratios (CR8) for Chemotherapy Drugs for Neuroblastoma in 2022
3.6 Chemotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.6.1 Chemotherapy Drugs for Neuroblastoma Market: Region Footprint
3.6.2 Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.6.3 Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Comparison
4.1.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Comparison
4.2.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Comparison
4.3.1 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.4.3 United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
4.5 China Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share
4.5.1 China Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.5.3 China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
4.6 Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Chemotherapy Drugs for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Cyclophosphamide
5.2.2 Cisplatin or Carboplatin
5.2.3 Vincristine
5.2.4 Doxorubicin (Adriamycin)
5.2.5 Etoposide
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Chemotherapy Drugs for Neuroblastoma Production by Type (2018-2029)
5.3.2 World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2018-2029)
5.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Chemotherapy Drugs for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Chemotherapy Drugs for Neuroblastoma Production by Application (2018-2029)
6.3.2 World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2018-2029)
6.3.3 World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Baxter Healthcare
7.1.1 Baxter Healthcare Details
7.1.2 Baxter Healthcare Major Business
7.1.3 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
7.1.4 Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Baxter Healthcare Recent Developments/Updates
7.1.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.2 Ingenus Pharmaceuticals
7.2.1 Ingenus Pharmaceuticals Details
7.2.2 Ingenus Pharmaceuticals Major Business
7.2.3 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.2.4 Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.2.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.3 ANI Pharmaceuticals
7.3.1 ANI Pharmaceuticals Details
7.3.2 ANI Pharmaceuticals Major Business
7.3.3 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.3.4 ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 ANI Pharmaceuticals Recent Developments/Updates
7.3.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.4 Teva Pharmaceuticals
7.4.1 Teva Pharmaceuticals Details
7.4.2 Teva Pharmaceuticals Major Business
7.4.3 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.4.4 Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Teva Pharmaceuticals Recent Developments/Updates
7.4.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Qilu Pharmaceutical
7.5.1 Qilu Pharmaceutical Details
7.5.2 Qilu Pharmaceutical Major Business
7.5.3 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
7.5.4 Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Qilu Pharmaceutical Recent Developments/Updates
7.5.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
7.6 Pfizer
7.6.1 Pfizer Details
7.6.2 Pfizer Major Business
7.6.3 Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
7.6.4 Pfizer Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Pfizer Recent Developments/Updates
7.6.6 Pfizer Competitive Strengths & Weaknesses
7.7 Hikma Pharmaceuticals
7.7.1 Hikma Pharmaceuticals Details
7.7.2 Hikma Pharmaceuticals Major Business
7.7.3 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
7.7.4 Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Hikma Pharmaceuticals Recent Developments/Updates
7.7.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Fresenius Kabi
7.8.1 Fresenius Kabi Details
7.8.2 Fresenius Kabi Major Business
7.8.3 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
7.8.4 Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.8.5 Fresenius Kabi Recent Developments/Updates
7.8.6 Fresenius Kabi Competitive Strengths & Weaknesses
7.9 Accord Healthcare
7.9.1 Accord Healthcare Details
7.9.2 Accord Healthcare Major Business
7.9.3 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
7.9.4 Accord Healthcare Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.9.5 Accord Healthcare Recent Developments/Updates
7.9.6 Accord Healthcare Competitive Strengths & Weaknesses
7.10 Viatris
7.10.1 Viatris Details
7.10.2 Viatris Major Business
7.10.3 Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
7.10.4 Viatris Chemotherapy Drugs for Neuroblastoma Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.10.5 Viatris Recent Developments/Updates
7.10.6 Viatris Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Chemotherapy Drugs for Neuroblastoma Industry Chain
8.2 Chemotherapy Drugs for Neuroblastoma Upstream Analysis
8.2.1 Chemotherapy Drugs for Neuroblastoma Core Raw Materials
8.2.2 Main Manufacturers of Chemotherapy Drugs for Neuroblastoma Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Chemotherapy Drugs for Neuroblastoma Production Mode
8.6 Chemotherapy Drugs for Neuroblastoma Procurement Model
8.7 Chemotherapy Drugs for Neuroblastoma Industry Sales Model and Sales Channels
8.7.1 Chemotherapy Drugs for Neuroblastoma Sales Model
8.7.2 Chemotherapy Drugs for Neuroblastoma Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018-2023) & (USD Million)
Table 3. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2024-2029) & (USD Million)
Table 4. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2023)
Table 5. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2024-2029)
Table 6. World Chemotherapy Drugs for Neuroblastoma Production by Region (2018-2023) & (K Units)
Table 7. World Chemotherapy Drugs for Neuroblastoma Production by Region (2024-2029) & (K Units)
Table 8. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2023)
Table 9. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2024-2029)
Table 10. World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Chemotherapy Drugs for Neuroblastoma Major Market Trends
Table 13. World Chemotherapy Drugs for Neuroblastoma Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Chemotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023) & (K Units)
Table 15. World Chemotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Chemotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Chemotherapy Drugs for Neuroblastoma Producers in 2022
Table 18. World Chemotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Chemotherapy Drugs for Neuroblastoma Producers in 2022
Table 20. World Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Chemotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
Table 22. World Chemotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Chemotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 24. Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 25. Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 26. Chemotherapy Drugs for Neuroblastoma Competitive Factors
Table 27. Chemotherapy Drugs for Neuroblastoma New Entrant and Capacity Expansion Plans
Table 28. Chemotherapy Drugs for Neuroblastoma Mergers & Acquisitions Activity
Table 29. United States VS China Chemotherapy Drugs for Neuroblastoma Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Chemotherapy Drugs for Neuroblastoma Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Chemotherapy Drugs for Neuroblastoma Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 37. China Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 42. Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 47. World Chemotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Chemotherapy Drugs for Neuroblastoma Production by Type (2018-2023) & (K Units)
Table 49. World Chemotherapy Drugs for Neuroblastoma Production by Type (2024-2029) & (K Units)
Table 50. World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2018-2023) & (USD Million)
Table 51. World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2024-2029) & (USD Million)
Table 52. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Chemotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Chemotherapy Drugs for Neuroblastoma Production by Application (2018-2023) & (K Units)
Table 56. World Chemotherapy Drugs for Neuroblastoma Production by Application (2024-2029) & (K Units)
Table 57. World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2018-2023) & (USD Million)
Table 58. World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2024-2029) & (USD Million)
Table 59. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 62. Baxter Healthcare Major Business
Table 63. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 64. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Baxter Healthcare Recent Developments/Updates
Table 66. Baxter Healthcare Competitive Strengths & Weaknesses
Table 67. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 68. Ingenus Pharmaceuticals Major Business
Table 69. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 70. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Ingenus Pharmaceuticals Recent Developments/Updates
Table 72. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 73. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 74. ANI Pharmaceuticals Major Business
Table 75. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 76. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. ANI Pharmaceuticals Recent Developments/Updates
Table 78. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 79. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. Teva Pharmaceuticals Major Business
Table 81. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 82. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Teva Pharmaceuticals Recent Developments/Updates
Table 84. Teva Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 86. Qilu Pharmaceutical Major Business
Table 87. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
Table 88. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Qilu Pharmaceutical Recent Developments/Updates
Table 90. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 91. Pfizer Basic Information, Manufacturing Base and Competitors
Table 92. Pfizer Major Business
Table 93. Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
Table 94. Pfizer Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Pfizer Recent Developments/Updates
Table 96. Pfizer Competitive Strengths & Weaknesses
Table 97. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 98. Hikma Pharmaceuticals Major Business
Table 99. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 100. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Hikma Pharmaceuticals Recent Developments/Updates
Table 102. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
Table 103. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 104. Fresenius Kabi Major Business
Table 105. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
Table 106. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Fresenius Kabi Recent Developments/Updates
Table 108. Fresenius Kabi Competitive Strengths & Weaknesses
Table 109. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 110. Accord Healthcare Major Business
Table 111. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 112. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Accord Healthcare Recent Developments/Updates
Table 114. Viatris Basic Information, Manufacturing Base and Competitors
Table 115. Viatris Major Business
Table 116. Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
Table 117. Viatris Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Chemotherapy Drugs for Neuroblastoma Upstream (Raw Materials)
Table 119. Chemotherapy Drugs for Neuroblastoma Typical Customers
Table 120. Chemotherapy Drugs for Neuroblastoma Typical Distributors
Table 1. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2018-2023) & (USD Million)
Table 3. World Chemotherapy Drugs for Neuroblastoma Production Value by Region (2024-2029) & (USD Million)
Table 4. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2023)
Table 5. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2024-2029)
Table 6. World Chemotherapy Drugs for Neuroblastoma Production by Region (2018-2023) & (K Units)
Table 7. World Chemotherapy Drugs for Neuroblastoma Production by Region (2024-2029) & (K Units)
Table 8. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2023)
Table 9. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2024-2029)
Table 10. World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Chemotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Chemotherapy Drugs for Neuroblastoma Major Market Trends
Table 13. World Chemotherapy Drugs for Neuroblastoma Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Chemotherapy Drugs for Neuroblastoma Consumption by Region (2018-2023) & (K Units)
Table 15. World Chemotherapy Drugs for Neuroblastoma Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Chemotherapy Drugs for Neuroblastoma Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Chemotherapy Drugs for Neuroblastoma Producers in 2022
Table 18. World Chemotherapy Drugs for Neuroblastoma Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Chemotherapy Drugs for Neuroblastoma Producers in 2022
Table 20. World Chemotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Chemotherapy Drugs for Neuroblastoma Company Evaluation Quadrant
Table 22. World Chemotherapy Drugs for Neuroblastoma Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Chemotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 24. Chemotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 25. Chemotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 26. Chemotherapy Drugs for Neuroblastoma Competitive Factors
Table 27. Chemotherapy Drugs for Neuroblastoma New Entrant and Capacity Expansion Plans
Table 28. Chemotherapy Drugs for Neuroblastoma Mergers & Acquisitions Activity
Table 29. United States VS China Chemotherapy Drugs for Neuroblastoma Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Chemotherapy Drugs for Neuroblastoma Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Chemotherapy Drugs for Neuroblastoma Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 37. China Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 42. Rest of World Based Chemotherapy Drugs for Neuroblastoma Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share (2018-2023)
Table 47. World Chemotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Chemotherapy Drugs for Neuroblastoma Production by Type (2018-2023) & (K Units)
Table 49. World Chemotherapy Drugs for Neuroblastoma Production by Type (2024-2029) & (K Units)
Table 50. World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2018-2023) & (USD Million)
Table 51. World Chemotherapy Drugs for Neuroblastoma Production Value by Type (2024-2029) & (USD Million)
Table 52. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Chemotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Chemotherapy Drugs for Neuroblastoma Production by Application (2018-2023) & (K Units)
Table 56. World Chemotherapy Drugs for Neuroblastoma Production by Application (2024-2029) & (K Units)
Table 57. World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2018-2023) & (USD Million)
Table 58. World Chemotherapy Drugs for Neuroblastoma Production Value by Application (2024-2029) & (USD Million)
Table 59. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 62. Baxter Healthcare Major Business
Table 63. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 64. Baxter Healthcare Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Baxter Healthcare Recent Developments/Updates
Table 66. Baxter Healthcare Competitive Strengths & Weaknesses
Table 67. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 68. Ingenus Pharmaceuticals Major Business
Table 69. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 70. Ingenus Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Ingenus Pharmaceuticals Recent Developments/Updates
Table 72. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 73. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 74. ANI Pharmaceuticals Major Business
Table 75. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 76. ANI Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. ANI Pharmaceuticals Recent Developments/Updates
Table 78. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 79. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 80. Teva Pharmaceuticals Major Business
Table 81. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 82. Teva Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Teva Pharmaceuticals Recent Developments/Updates
Table 84. Teva Pharmaceuticals Competitive Strengths & Weaknesses
Table 85. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 86. Qilu Pharmaceutical Major Business
Table 87. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Product and Services
Table 88. Qilu Pharmaceutical Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Qilu Pharmaceutical Recent Developments/Updates
Table 90. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 91. Pfizer Basic Information, Manufacturing Base and Competitors
Table 92. Pfizer Major Business
Table 93. Pfizer Chemotherapy Drugs for Neuroblastoma Product and Services
Table 94. Pfizer Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Pfizer Recent Developments/Updates
Table 96. Pfizer Competitive Strengths & Weaknesses
Table 97. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 98. Hikma Pharmaceuticals Major Business
Table 99. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Product and Services
Table 100. Hikma Pharmaceuticals Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 101. Hikma Pharmaceuticals Recent Developments/Updates
Table 102. Hikma Pharmaceuticals Competitive Strengths & Weaknesses
Table 103. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 104. Fresenius Kabi Major Business
Table 105. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Product and Services
Table 106. Fresenius Kabi Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 107. Fresenius Kabi Recent Developments/Updates
Table 108. Fresenius Kabi Competitive Strengths & Weaknesses
Table 109. Accord Healthcare Basic Information, Manufacturing Base and Competitors
Table 110. Accord Healthcare Major Business
Table 111. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Product and Services
Table 112. Accord Healthcare Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 113. Accord Healthcare Recent Developments/Updates
Table 114. Viatris Basic Information, Manufacturing Base and Competitors
Table 115. Viatris Major Business
Table 116. Viatris Chemotherapy Drugs for Neuroblastoma Product and Services
Table 117. Viatris Chemotherapy Drugs for Neuroblastoma Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 118. Global Key Players of Chemotherapy Drugs for Neuroblastoma Upstream (Raw Materials)
Table 119. Chemotherapy Drugs for Neuroblastoma Typical Customers
Table 120. Chemotherapy Drugs for Neuroblastoma Typical Distributors
LIST OF FIGURES
Figure 1. Chemotherapy Drugs for Neuroblastoma Picture
Figure 2. World Chemotherapy Drugs for Neuroblastoma Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Chemotherapy Drugs for Neuroblastoma Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 5. World Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 6. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2029)
Figure 7. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2029)
Figure 8. North America Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 9. Europe Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 10. China Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 11. Japan Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 12. Chemotherapy Drugs for Neuroblastoma Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 15. World Chemotherapy Drugs for Neuroblastoma Consumption Market Share by Region (2018-2029)
Figure 16. United States Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 17. China Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 18. Europe Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 19. Japan Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 20. South Korea Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 22. India Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Chemotherapy Drugs for Neuroblastoma Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Chemotherapy Drugs for Neuroblastoma Markets in 2022
Figure 26. United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Chemotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 30. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 32. World Chemotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Type in 2022
Figure 34. Cyclophosphamide
Figure 35. Cisplatin or Carboplatin
Figure 36. Vincristine
Figure 37. Doxorubicin (Adriamycin)
Figure 38. Etoposide
Figure 39. Other
Figure 40. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Type (2018-2029)
Figure 41. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Type (2018-2029)
Figure 42. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 43. World Chemotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 44. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Application in 2022
Figure 45. Hospital
Figure 46. Clinic
Figure 47. Other
Figure 48. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Application (2018-2029)
Figure 49. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Application (2018-2029)
Figure 50. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 51. Chemotherapy Drugs for Neuroblastoma Industry Chain
Figure 52. Chemotherapy Drugs for Neuroblastoma Procurement Model
Figure 53. Chemotherapy Drugs for Neuroblastoma Sales Model
Figure 54. Chemotherapy Drugs for Neuroblastoma Sales Channels, Direct Sales, and Distribution
Figure 55. Methodology
Figure 56. Research Process and Data Source
Figure 1. Chemotherapy Drugs for Neuroblastoma Picture
Figure 2. World Chemotherapy Drugs for Neuroblastoma Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Chemotherapy Drugs for Neuroblastoma Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 5. World Chemotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 6. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Region (2018-2029)
Figure 7. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Region (2018-2029)
Figure 8. North America Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 9. Europe Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 10. China Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 11. Japan Chemotherapy Drugs for Neuroblastoma Production (2018-2029) & (K Units)
Figure 12. Chemotherapy Drugs for Neuroblastoma Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 15. World Chemotherapy Drugs for Neuroblastoma Consumption Market Share by Region (2018-2029)
Figure 16. United States Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 17. China Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 18. Europe Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 19. Japan Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 20. South Korea Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 22. India Chemotherapy Drugs for Neuroblastoma Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Chemotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Chemotherapy Drugs for Neuroblastoma Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Chemotherapy Drugs for Neuroblastoma Markets in 2022
Figure 26. United States VS China: Chemotherapy Drugs for Neuroblastoma Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Chemotherapy Drugs for Neuroblastoma Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Chemotherapy Drugs for Neuroblastoma Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 30. China Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Chemotherapy Drugs for Neuroblastoma Production Market Share 2022
Figure 32. World Chemotherapy Drugs for Neuroblastoma Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Type in 2022
Figure 34. Cyclophosphamide
Figure 35. Cisplatin or Carboplatin
Figure 36. Vincristine
Figure 37. Doxorubicin (Adriamycin)
Figure 38. Etoposide
Figure 39. Other
Figure 40. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Type (2018-2029)
Figure 41. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Type (2018-2029)
Figure 42. World Chemotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 43. World Chemotherapy Drugs for Neuroblastoma Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 44. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Application in 2022
Figure 45. Hospital
Figure 46. Clinic
Figure 47. Other
Figure 48. World Chemotherapy Drugs for Neuroblastoma Production Market Share by Application (2018-2029)
Figure 49. World Chemotherapy Drugs for Neuroblastoma Production Value Market Share by Application (2018-2029)
Figure 50. World Chemotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 51. Chemotherapy Drugs for Neuroblastoma Industry Chain
Figure 52. Chemotherapy Drugs for Neuroblastoma Procurement Model
Figure 53. Chemotherapy Drugs for Neuroblastoma Sales Model
Figure 54. Chemotherapy Drugs for Neuroblastoma Sales Channels, Direct Sales, and Distribution
Figure 55. Methodology
Figure 56. Research Process and Data Source
